With a registered capital of 90.8 million US dollars, Aurovitas is a wholly-owned subsidiary of Aurobindo Pharma Ltd. in India.
Aurobindo Pharma is the second largest listed pharmaceutical company in India, which is a large multinational company with factories or offices in China, the United States, Europe, South America and South Africa. The headquarter has a total of 350 approved US generic drugs, which is more than the sum of drugs by all China pharmaceutical companies approved in the United States. It ranks first in the global sales of APIs and among the top of the pharmaceutical companies. The Headquarter, owning the world's leading R&D center, has more than 20,000 employees all over the world, which developed more than 150 markets with annual sales of more than 26 billion US dollars.
The total investment of Aurovitas Pharma Taizhou is 100 million US dollars. This plant covers an area of approximately 97 mu, with a total construction area of 81,700 square meters. The proposed formulation includes tablet and hard capsule with an annual production capacity of 10 billion tablets and 5.5 billion capsules.
